A Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.
In one line a RMAT is an approved shortcut.
Just awarded to Kyverna's 101
Relevance to us? Again the vector and knowhow for this product, see |
Speaking of relaxed people, this guy is the boss of Arcellx.
The lead programme he talks about there (CART-ddBCMA) is the one where OXB supply the vector.
See
And
I only mention this because those 3 years of the initial agreement will be up by the end of this year. Maybe we will see an RNS for that and maybe it will simply remain hidden in the yet to be seen KPI table. |
 He always seems very relaxed Cousin, which I think is just his style. I'm sure you are correct that Frank will naturally look to build a team which which reflects what he "knows" from his previous success and of course he has already recruited people to OXB who are known quantities to him from Rentschler Biopharma.
Last thing Stuart needs is a reference from me, but I think he has been a good CFO for OXB and an excellent, enthusiastic presenter from his early days (a time when OXB did struggle a bit with corporate presentations which were, if I'm honest, pretty unremarkable considering some of the things they were announcing).
I'm still of the opinion above, namely:-
The new CFO started work as a scientist and has that knowledge advantage.
The new CFO is extremely well qualified scientifically.
I'd bet another pound of Dom's money that she is fluent in French and German.
Finally, with the DEI/ESG/GKW obligations on all companies now it's quite helpful for Frank to have a woman in that position too. I'm sure that was not the primary reason but it's a very useful bonus. |
Have to say, not having met Stuart before, that he gave a very chilled vibe at the AGM.
Frank appeared a very different character. Clearly driven, very structured and precise in his language and (other than the few hints at humour) no real flourishes.
I can imagine that the make up of thew senior leadership team is more in the Frank image than that of Stuart (although that the chilled vibe may have been in the full knowledge that it was his last time to go through the AGM 'pantomime' with OXB!) |
Change of CFO seems to have dampened the enthusiasm of buyers! |
Does anyone from the Senior Management team ever go to the offices? I thought they were a "Distributed Team"? |
Always reassuring to have a competent CFO but I'm never quite sure what it does for the share price if the old one knew what he/she was doing. Does the fact that she has a strong background in investment management and M&A accounting perhaps give an indicator of the future direction of flight of OXB? |
Well, at least Lucy will know where the Executive Offices are in Oxford, it is the office previously used by Woodford Investment Management...... |
Interesting. Must have been intimately involved in the NVS takeover if the CFO "Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team across the US and Germany until the closing of the acquisition of the company by Novartis. " |
Here it isOxford Biomedica PLC - OXB announces CFO transition #OXB @OxfordBioMedic HTTps://www.voxmarkets.co.uk/rns/announcement/26d73225-16d5-4e74-bb9b-c1d21e6ce0c9 #voxmarkets |
Good RNS announcement. Ms Crabree has a very impressive CV both as a PhD Scientist and having worked in top market based institutions. Possibly only slightly tarnished by the name Woodford Investment Management (only joking, a brilliant appointment). Well done Stuart Paynter, doesn't sound like he intends retiring, it will be interesting to see what he does next. |
I'm the first to bat for OXB, but I just opened that first datasheet
And then remembered the recently updated website page
New factsheet 320+ batches with 8,000+ patients treated.
Website 340+ batches with 6,000+ patients treated.
I'm sure people looking to buy the best vector aren't going to be swayed by that, but it seems a little careless - doesn't it? |
Beat me to it PB ;)
Just out from OXB
Our LentiVector® platform, the world’s first lentiviral-based gene delivery system to be commercially approved, has already helped thousands of patients receive innovative and life-changing ex vivo and in vivo treatments.
In our 4 new factsheets, discover how we can rapidly bring your cell and gene therapies to market.
Download our fact sheets below:
•LentiVector® Platform
•Analytics for Lentiviral Vectors
•Clinical & Commercial Manufacturing of Lentiviral Vectors
•LentiStable™ High-titre Stable Producer Cell Lines
Need more information? Get in touch with our team!
We are a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene therapies that transform patients’ lives.
You can contact our team at partnering@oxb.com and we’ll be happy to discuss more details with you!
Let’s do something life-changing together! |
Nice email sent to subscribers!HTTps://mailchi.mp/d14a411e4bbf/our-new-factsheets-are-available-for-download?e=236e850ed3 |
Thanks Sean, I'm at peace with my OXB holding and I'm pretty confident that anything important will come to us via the official route.
I try to keep a running update on here because we as a thread tend to get very impatient quite quickly. We had a brilliant presentation at the end of April. Those who went to the AGM at the end of June got told that everything was on track. OK the only RNS news of significance we have had since the results was IM paying us £17m for new shares, but if you think about it - full presentation end of April then informal update end of June - you can sort of forgive Frank for maybe thinking "well, the shareholders should all know the plan".
Keeping the running commentary is a reassuring thing for me (we should all know our shares) and sharing some of it on here costs me nothing, but it's also a bit of a mixed bag as everyone loves you in a bull market but in a dark period then it's often a less welcome view.
An example here would be the Homology purchase (more accurately the purchase of their GMP production facilities and the rights to their AAV vector). That went down like a lead balloon on here, but at the results 10 weeks ago, I'm sure we all noticed slide 11
So out of the 30 contracts OXB signed in 2023 (left of slide) 41% were AAV (right of slide). In other words it's now coming good for us in the bigger vector market.
Can you imagine what a difference that made to not only our reported figures but more importantly our prospects?
OXB have recently reaffirmed better than 35% annual growth over the next 3 years but it's 10 weeks ago now so...
I genuinely do expect big news soon. At the very least we are going to find out who the commercial multiple myeloma supply contract is for and what it is worth to us, but I'm quite confident for something bigger. |
For completeness I should point out that they also said....Also, in case you use Linkedin you may find it interesting to follow updates on the OXB profile here we post on various topics including scientific publications and industry news. https://www.linkedin.com/company/oxford-biomedica |
Yep, it almost certainly means that they are waiting for something to happen and would like one big announcement. Why they would want to do that I've no idea.
If they are doing proper quarterly reporting (and they didn't mention that at the results - only saying they would update the KPI table regularly) then they would have to wait for the auditors, so it may be to do with that - but if they are just planning on a "it's all going very well and here are the headline figures" mid term update, then couldn't they just add a note that those are unaudited figures?
I realise not everyone agrees with the reasoning, but it's extremely unusual for none of the senior staff to buy any during the post results open periods. Last time none of them bought then 6 months later came the ABL announcement. I would expect something significant soon with the mid-term update tagged onto it.
Almost certainly not a fundraising out of need as they turned the year with £100m+ and just got another £17m from IM. |
I too got the response from OXB that somebody else (sorry can't remember who) posted the other day...Yes, we have a commitment to putting out more regular updates. Our aim is to provide updates on a quarterly basis (including our regular full year and half year financial results). Since this is the first year of doing this we do not have a fixed routine of these yet, but we are aiming for the next one to be between now and September. In future you should expect these updates to be more predictable in timing.Sort of reassuring but can't help but feel 'the next one to be between now and September' is extremely ambiguous - in true OXB style! |
Sounds right Plutonian,
The three universities that make up the UK Respiratory Gene Therapy Consortium (GTC) have developed a gene transfer agent with great promise for the treatment of cystic fibrosis, which has been licensed to the pharmaceutical company Boehringer Ingelheim.
AlveoGene will take the same lentiviral vector technology and explore its application in other diseases, principally involving the lungs. Its first target will be alpha-1 antitrypsin (AAT) deficiency,
Preclinical work carried out with the GTC’s lentiviral vector
In its first year working on AAT deficiency Alveogene will continue to collaborate closely with the researchers in the GTC.
market size of approximately $6B by 2030
Idiopathic Pulmonary Fibrosis (IPF)
AVG-004 uses the same proprietary lentiviral vector that is used for both AVG-001, AVG-002 and AVG-003 to deliver the relevant transgene to the lung.
AVG-001 for Alpha-1 Antitrypsin Deficiency (AATD)
market for AATD at circa $1Bn rising to $3Bn |
#8286 Because it almost always is "like a long tedious journey to nowhere". |
Summer holidays soon, so now news for a few weeks, here's hoping for a blockbuster Autumn. Some how. i very much doubt it. Although i have done relatively well out of OXB, why does it always feel like a long tedious journey to nowhere 555 |
I like that thinking Plutonian and will add it to the list as a very likely possibility.
"New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)
AlveoGene initially aims to leverage proprietary lentiviral gene therapy platform designed and developed by GTC specifically for inhaled delivery"
OXB in that GTC as you note.
"the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB)" |
Harry, as you may have guessed, I also have a list covering most of those names (and a few other possibilities).
AlveoGene is also on my list, with AVG-001 for Alpha-1 Antitrypsin Deficiency.
AlveoGene licensed the CF programme to Boehringer Ingelheim, but reserved all other indications for the same technology. I assumed this included the OXB lenitvector technology, but I may be overthinking. |
Mid price above bid / ask since that opening trade. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
